1.73
-0.01(-0.57%)
Currency In USD
| Previous Close | 1.74 |
| Open | 1.75 |
| Day High | 1.84 |
| Day Low | 1.72 |
| 52-Week High | 2.64 |
| 52-Week Low | 0.53 |
| Volume | 2.53M |
| Average Volume | 5.11M |
| Market Cap | 257.78M |
| PE | -0.84 |
| EPS | -2.07 |
| Moving Average 50 Days | 1.87 |
| Moving Average 200 Days | 1.29 |
| Change | -0.01 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of February 14, 2026 at a share price of $1.73. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.19 as of February 14, 2026 at a share price of $1.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
GlobeNewswire Inc.
Feb 09, 2026 2:00 PM GMT
Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage bi
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 05, 2026 1:45 PM GMT
Virtual presentation scheduled for Thursday, February 26th at 12:40 PM ET Access the webcast here Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical c
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
GlobeNewswire Inc.
Jan 29, 2026 1:45 PM GMT
Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s disease, and late-stage clinical trial design Appointments strengthen Palisade Bio’s clinical strategy as PALI-2108 advances to